Multiple Novel Ceftazidime-Avibactam-Resistant Variants of <i>bla</i> <sub>KPC-2</sub> -Positive Klebsiella pneumoniae in Two Patients-Reference-Cited by-同舟云学术

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of bla _KPC-2 -Positive Klebsiella pneumoniae in Two Patients

Published:2022-06-29 Issue:3 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Shi Qingyu¹²,Han Renru¹²,Guo Yan¹²,Yang Yang¹²,Wu Shi¹²,Ding Li¹²,Zhang Rong³,Yin Dandan¹²,Hu Fupin¹²^ORCID

Affiliation:

1. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China

2. Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China

3. Department of Clinical Laboratory Medicine, Second Affiliated Hospital of Zhejiang University, Hangzhou, China

Abstract

Carbapenem-resistant K. pneumoniae which was classified as the most urgent threat by World Health Organization, is the most critical public health concern due to its high mortality rate. Recently, the rapid mutation of bla KPC has occurred during anti-infective therapy, which posed an unexpected challenge for both the diagnostic laboratory and clinical practice.

Funder

China Antimicrobial Surveillance Network

MOST | National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01714-21

Reference53 articles.

1. Treating infections caused by carbapenemase-producing Enterobacteriaceae

2. Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States 2019. U.S. Department of Health and Human Services CDC Atlanta GA. www.cdc.gov/DrugResistance/Biggest-Threats.html. Accessed January 2 2021.

3. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study

4. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria

5. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modification of carbapenemase inhibition test and comparison of its performance with NG-Test CARBA 5 for detection of carbapenemase-producing Enterobacterales;Journal of Applied Microbiology;2024-08

2. Comparison of three colloidal gold immunoassays and GeneXpert Carba-R for the detection of Klebsiella pneumoniae bla _KPC-2 variants;Journal of Clinical Microbiology;2024-07-16

3. Detection of hidden antibiotic resistance through real-time genomics;Nature Communications;2024-06-28

4. Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime–Avibactam in an ST11 Klebsiella pneumoniae Strain;Microorganisms;2024-06-13

5. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae;Emerging Microbes & Infections;2024-06-12